Clinical evaluation of a formulation containing Curcuma longa and Boswellia serrata extracts in the management of knee osteoarthritis

Molecular Medicine Reports

Volumn 8, Issue 5, 2013, Pages 1542-1548

  Kizhakkedath, Reji ^a  

^a Anugraha Medical Centre   (India)

Author keywords

Boswellic acid; Curcumin; Joint pain; Osteoarthritis; Swelling

Indexed keywords

ANTIRHEUMATIC AGENT; BOSWELLIA SERRATA EXTRACT PLUS CURCUMA LONGA EXTRACT; CELECOXIB; CURCUMIN; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; ESSENTIAL OIL; TURMERIC; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BOSWELLIA SERRATA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CURCUMA LONGA; DISEASE SEVERITY; DRUG FORMULATION; DRUG TOLERABILITY; EOSINOPHIL COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; KIDNEY FUNCTION TEST; KNEE OSTEOARTHRITIS; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LYMPHOCYTE COUNT; MALE; SIDE EFFECT; TREATMENT RESPONSE; UREA BLOOD LEVEL; VITAL SIGN;

ADOLESCENT; ADULT; AGED; BOSWELLIA; CURCUMA; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PHYTOTHERAPY; PLANT EXTRACTS; PROGNOSIS; SAFETY; YOUNG ADULT;

EID: 84885110104     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1661     Document Type: Article

References (26)

1. Dillion CF, Hirsch R, Rasch EK and Gu Q: Symptomatic hand osteoarthritis in the United States: prevalence and functional impairment estimates from the third U.S. National Health and Nutrition Examination Survey 1991-1994. Am J Phys Med Rehabil 86: 12-21, 2007.
2. Fautrel B, Hilliquin P, Rozenberg S, et al: Impact of osteoarthritis: results of nationwide survey of 10,000 patients consulting for OA. Joint Bone Spine 72: 235-240, 2005.
3. Rabenda V, Manette C, Lemmens R, et al: Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol 33: 1152-1158, 2006.
4. Gabriel SE, Crowson CS, Campion ME and O'Fallon WM: Direct medical costs unique to people with arthritis. J Rheumatol 24: 719-725, 1997.
5. Gupta S, Hawker GA, Laporte A, Croxford R and Coyte PC: The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatology (Oxford) 44: 1531-1537, 2005.
6. Le Pen C, Reygrobellet C and Gérentes I: Financial costs of osteoarthritis in France. The 'COART' France study. Joint Bone Spine 72: 567-570, 2005.
7. Zhang W, Moskowitz RW, Nuki G, et al: OARSI recommendations for the management of hip and knee osteoarthritis, Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 15: 981-1000, 2007.
8. Zhang W, Moskowitz RW, Nuki G, et al: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16: 137-162, 2008.
9. Zhang W, Doherty M, Arden N, et al: EULAR evidence-based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64: 669-681, 2005.
10. Zhang W, Doherty M, Leeb BF, et al: EULAR evidence-based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66: 377-388, 2007.
11. Jordan KM, Arden NK, Doherty M, et al: EULAR Recommendations 2003: an evidence-based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 62: 1145-1155, 2003.
12. Pincus T, Koch GG, Sokka T, et al: A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 44: 1587-1598, 2001.
13. Case JP, Baliunas AJ and Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 163: 169-178, 2003.
14. Gupta I, Gupta V, Parihar A, et al: Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 3: 511-514, 1998.
15. Sander O, Herborn G and Rau R: Is H15 (resin extract of Boswellia serrata, 'incense') a useful supplement to establish drug therapy of chronic polyarthritis? Results of a double-blind pilot study. Z Rheumatol 57: 11-16, 1998 (In German).
16. Gerhardt H, Seifert F, Buvari P, et al: Therapy of active Crohn disease with Boswellia serrata extract H15. Z Gastroenterol 39: 11-17, 2001 (In German).
17. Kimmatkar N, Thawani V, Hingorani L and Khiyani R: Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee - a randomized, double-blind, placebo-controlled trial. Phytomedicine 10: 3-7, 2003.
18. Sontakke S, Thawani V, Pimpalkhute P, et al: Open, randomized, controlled clinical trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of the knee. Indian J Pharmacol 39: 27-29, 2007.
19. Sengupta K, Alluri KV, Satish AR, et al: A double-blind, randomized, placebo-controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther 10: R85, 2008.
20. Madisch A, Miehlke S, Eichele O, et al: Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis 22: 1445-1451, 2007.
21. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR and Ammon HP: Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 261: 1143-1146, 1992.
22. Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon HP and Safayhi H: Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 117: 615-618, 1996.
23. Sailer ER, Schweizer S, Boden SE, Ammon HP and Safayhi H: Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem 256: 364-368, 1998.
24. Liu JJ, Nilsson A, Oredsson S, Badmaev V, Zhao WZ and Duan RD: Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 23: 2087-2093, 2002.
25. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R and Srinivas PS: Influence of piperine in pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356, 1998.
26. Schweizer S, von Brocke AF, Boden SE, Bayer E, Ammon HP and Safayhi H: Workup-dependent formation of 5-lipoxygenase-inhibitory boswellic acid analogues. J Nat Prod 63: 1058-1061, 2000.